Cargando…
Prevalence of persistent lipid abnormalities in statin-treated patients: Belgian results of the Dyslipidaemia International Study (DYSIS)
AIM: A substantial number of cardiovascular events are not prevented by statin therapy, which is still regarded as the first-line therapy for hyperlipidaemia. Insights into the prevalence of lipid abnormalities of statin-treated patients in Belgium are lacking and may shed light on an unmet medical...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265243/ https://www.ncbi.nlm.nih.gov/pubmed/24308644 http://dx.doi.org/10.1111/ijcp.12315 |
_version_ | 1782348850150768640 |
---|---|
author | Devroey, D Radermecker, R P Van der Schueren, B J Torbeyns, B Jaken, R J |
author_facet | Devroey, D Radermecker, R P Van der Schueren, B J Torbeyns, B Jaken, R J |
author_sort | Devroey, D |
collection | PubMed |
description | AIM: A substantial number of cardiovascular events are not prevented by statin therapy, which is still regarded as the first-line therapy for hyperlipidaemia. Insights into the prevalence of lipid abnormalities of statin-treated patients in Belgium are lacking and may shed light on an unmet medical need for optimal use of current lipid-lowering therapies. This study aims to assess the prevalence and types of persistent lipid abnormalities in patients receiving statin therapy in a real-life primary care setting in Belgium. METHODS: This cross-sectional cohort study was designed to estimate the prevalence of specific lipid abnormalities in statin-treated patients in Belgium. Total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides were recorded from the patients' medical record. Patient's total cardiovascular risk and corresponding lipid treatment goals were defined based on the recent European Society of Cardiology/European Atherosclerosis Society recommendations. RESULTS: Overall, 56.2% of the statin-treated patients were not at goal for LDL-C. Low HDL-C (< 40 mg dl(−1) in men, < 45 mg dl(−1) in women) and elevated triglycerides (> 150 mg dl(−1)) were seen in 16.3% and 29.0% of patients, respectively. Very high-risk patients were more likely to have LDL-C not at goal (71.4% of them), while 60.0% of high-risk patients and 34.1% of moderate-risk patients were not at goal for LDL-C. Use of ezetimibe (10 mg) was strongly associated with meeting LDL-C goals (OR 16.9, p < 0.0001). CONCLUSION: In Belgium, lipid abnormalities remained highly prevalent despite statin treatment, with more than half of all patients not reaching their LDL-C treatment goal. This finding clearly indicates that more aggressive lipid-lowering treatment is required in clinical daily practice to achieve the goals of the current guidelines. |
format | Online Article Text |
id | pubmed-4265243 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BlackWell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-42652432014-12-23 Prevalence of persistent lipid abnormalities in statin-treated patients: Belgian results of the Dyslipidaemia International Study (DYSIS) Devroey, D Radermecker, R P Van der Schueren, B J Torbeyns, B Jaken, R J Int J Clin Pract Cardiovascular AIM: A substantial number of cardiovascular events are not prevented by statin therapy, which is still regarded as the first-line therapy for hyperlipidaemia. Insights into the prevalence of lipid abnormalities of statin-treated patients in Belgium are lacking and may shed light on an unmet medical need for optimal use of current lipid-lowering therapies. This study aims to assess the prevalence and types of persistent lipid abnormalities in patients receiving statin therapy in a real-life primary care setting in Belgium. METHODS: This cross-sectional cohort study was designed to estimate the prevalence of specific lipid abnormalities in statin-treated patients in Belgium. Total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides were recorded from the patients' medical record. Patient's total cardiovascular risk and corresponding lipid treatment goals were defined based on the recent European Society of Cardiology/European Atherosclerosis Society recommendations. RESULTS: Overall, 56.2% of the statin-treated patients were not at goal for LDL-C. Low HDL-C (< 40 mg dl(−1) in men, < 45 mg dl(−1) in women) and elevated triglycerides (> 150 mg dl(−1)) were seen in 16.3% and 29.0% of patients, respectively. Very high-risk patients were more likely to have LDL-C not at goal (71.4% of them), while 60.0% of high-risk patients and 34.1% of moderate-risk patients were not at goal for LDL-C. Use of ezetimibe (10 mg) was strongly associated with meeting LDL-C goals (OR 16.9, p < 0.0001). CONCLUSION: In Belgium, lipid abnormalities remained highly prevalent despite statin treatment, with more than half of all patients not reaching their LDL-C treatment goal. This finding clearly indicates that more aggressive lipid-lowering treatment is required in clinical daily practice to achieve the goals of the current guidelines. BlackWell Publishing Ltd 2014-02 2013-12-06 /pmc/articles/PMC4265243/ /pubmed/24308644 http://dx.doi.org/10.1111/ijcp.12315 Text en © 2013 The Authors. International Journal of Clinical Practice Published by John Wiley & Sons Ltd http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Cardiovascular Devroey, D Radermecker, R P Van der Schueren, B J Torbeyns, B Jaken, R J Prevalence of persistent lipid abnormalities in statin-treated patients: Belgian results of the Dyslipidaemia International Study (DYSIS) |
title | Prevalence of persistent lipid abnormalities in statin-treated patients: Belgian results of the Dyslipidaemia International Study (DYSIS) |
title_full | Prevalence of persistent lipid abnormalities in statin-treated patients: Belgian results of the Dyslipidaemia International Study (DYSIS) |
title_fullStr | Prevalence of persistent lipid abnormalities in statin-treated patients: Belgian results of the Dyslipidaemia International Study (DYSIS) |
title_full_unstemmed | Prevalence of persistent lipid abnormalities in statin-treated patients: Belgian results of the Dyslipidaemia International Study (DYSIS) |
title_short | Prevalence of persistent lipid abnormalities in statin-treated patients: Belgian results of the Dyslipidaemia International Study (DYSIS) |
title_sort | prevalence of persistent lipid abnormalities in statin-treated patients: belgian results of the dyslipidaemia international study (dysis) |
topic | Cardiovascular |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265243/ https://www.ncbi.nlm.nih.gov/pubmed/24308644 http://dx.doi.org/10.1111/ijcp.12315 |
work_keys_str_mv | AT devroeyd prevalenceofpersistentlipidabnormalitiesinstatintreatedpatientsbelgianresultsofthedyslipidaemiainternationalstudydysis AT radermeckerrp prevalenceofpersistentlipidabnormalitiesinstatintreatedpatientsbelgianresultsofthedyslipidaemiainternationalstudydysis AT vanderschuerenbj prevalenceofpersistentlipidabnormalitiesinstatintreatedpatientsbelgianresultsofthedyslipidaemiainternationalstudydysis AT torbeynsb prevalenceofpersistentlipidabnormalitiesinstatintreatedpatientsbelgianresultsofthedyslipidaemiainternationalstudydysis AT jakenrj prevalenceofpersistentlipidabnormalitiesinstatintreatedpatientsbelgianresultsofthedyslipidaemiainternationalstudydysis |